[Elsevier] TWO PAPERS FROM Endocrinology and Metabolism Clinics of North America (September 2026)

Waltersport Post time 5 day(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-09-15 20:20
Reward60points

Combination of Glucagon-like Peptide-1 Receptor Agonists and Sodium–Glucose Cotransporter Inhibitors in Type 1 Diabetes: Why, when and How? An Exploration of the Rationale and Clinical Scenarios for Combining These 2 Adjunctive Agents
10.1016/j.ecl.2026.04.009


Emerging Evidence for Cardiorenal Protection with Sodium–Glucose Cotransporter Inhibitors, Glucagon-like peptide-1 Receptor Agonists, and Mineralocorticoid Receptor Blockers in People with Type 1 Diabete
10.1016/j.ecl.2026.04.007

Best Answer

Please approve

View Full Content

Reply

Use magic Donate Report

All Reply1 Show all posts
Abdo-hagag Post time 5 day(s) ago | Show all posts

This post has been completed

Completed attachments will be deleted within 24 hours.
Reply

Use magic Donate Report

Return to the list